Skip to content

Application of 99mTc-Dar2 SPECT/CT in breast cancer imaging

Application of 99mTc-Dar2 SPECT/CT in breast cancer imaging

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053809
Enrollment
Unknown
Registered
2021-11-29
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Distant metastasis of breast cancer

Interventions

case series:None

Sponsors

Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years, pathological diagnosis can be obtained by surgery or biopsy. 2. Clinically diagnosed or diagnosed breast cancer. 3. Biopsy has confirmed tumor in some organs. 4. An informed consent form must be signed in writing by the subject or his legal guardian or caregiver. 5. If necessary, the subject may be accompanied by a caregiver. 6. Subjects or their legal representatives understand and sign written informed consent prior to any evaluation. 7. Female subjects must have medical records to prove that they have been sterilized by surgery (such as hysterectomy, bilateral oophorectomy or tubal ligation) or menopause for more than one year; if there is still the ability to conceive, isolation contraceptive measures must be taken during this study period. 8. Willingness and ability to cooperate with all projects of this research.

Exclusion criteria

Exclusion criteria: 1. Suffering from gastrointestinal, cardiovascular, renal, blood system, endocrine, respiratory system, immunodeficiency or other serious diseases. 2. In the past year, due to other clinical medical or scientific research needs, received ionizing radiation outside the scope of this experiment, so that the annual radiation exposure dose exceeded 50 mSv. 3. History of drug or alcohol abuse. 4. Pregnant or lactating patients. 5. The venous condition is poor and cannot tolerate repeated venipuncture. 6. Received experimental drug or device treatment (with unclear effect or safety) within 1 month. 7. May be allergic to the components of 99mTc-Dar2 injection. 8. Have any conditions that the host of this study believes that any link related to this experiment may cause harm or have potential harm.

Design outcomes

Primary

MeasureTime frame
Comparison of the correlation between 99mTc-Dar2 uptake and integrin a6 expression levels in tumor tissues;

Countries

China

Contacts

Public ContactSong Erwei

Sun Yat-sen Memorial Hospital of Sun Yat-sen University

songew@mail.sysu.edu.cn+86 20 81332507

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026